A comparative study on efficacy, safety and tolerability of topical tofacitinib vs topical tofacitinib combined with puvasol in the management of vitiligo

A prospective, comparative, randomised study on efficacy, safety and tolerability of topical tofacitinib vs topical tofacitinib with puvasol in the management of vitiligo. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/12/060436

Enrollment

Registered

2023-12-01

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: 2% Topical tofacitinib cream: 2% topical tofacitinib cream applied twice daily for 4 months Control Intervention1: 2% Topical tofacitinib cream with oral puvasol: 2% topical tofacitinib

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients who are clinically diagnosed cases of vitiligo 2)Both sexes – males and females 3)Age – above 12 years to 60 years 4)Body surface area involving the depigmented patches of less than 10% 5)Depigmented patches in exposed areas of the body

Exclusion criteria

Exclusion criteria: 1)Patients having vitiligo patches in more than 10% BSA and having patches over flexure areas and genitals 2)Patients with active or latent TB 3)Patients with anaemia (Hb 4)Patients with malignancies or lymphoproliferative disorders 5)Patients on potent immunosuppresants, biological DMARDS , H/O organ transplant 6)Patients with deranged lipid profile 7)H/O recent live vaccination 8)Age less than 12 years, pregnancy and lactation 9)Family history of melanoma/non melanoma skin cancers 10)People suffering from photosensitivity disorders

Design outcomes

Primary

Measure	Time frame
To assess the clinical efficacy of topical tofacitinib vs topical tofacitinib with puvasol in vitiligo patients with respect to repigmentation of skinTimepoint: 4 months	—

Secondary

Measure	Time frame
To know the safety and tolerability of topical tofacitinib vs topical tofacitinib with puvasol in treatment of vitiligo. Timepoint: 4 months	—

Countries

India

Contacts

Public ContactRohini Amar Rathod

Shri Bhausaheb Hire Government Medical College and Hospital, Dhule

drchetanrajput@yahoo.com8983758338

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026